Taxotere®
Docetaxel is a semi-synthetic taxane that disrupts microtubule dynamics. Used in breast, prostate, gastric, head and neck, and non-small cell lung cancers.
| Dosage Form | IV Injectable (Concentrate for Solution) |
| Strength | 20 mg/mL, 80 mg/4mL |
| Storage | Store at 2–25°C. Protect from light. |
| Category | Oncology |
| Availability | Available for Transfer |
Breast cancer; NSCLC; hormone-refractory prostate cancer; gastric adenocarcinoma; head and neck squamous cell carcinoma.
Promotes assembly of microtubules and inhibits their depolymerization, stabilizing them and disrupting the microtubule dynamics required for mitotic cell division.
Each Burrard Pharmaceuticals technology transfer package for Docetaxel includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier sections for a named territory, scoped per programme.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Scope and timing for the complete know-how package are confirmed in writing after a confidentiality agreement. Book a consultation to discuss your specific requirements.